Prevalence and molecular characterization of AmpC-producing clinical isolates of escherichia coli from southeastern Iran

Microbial Drug Resistance

Volumn 20, Issue 2, 2014, Pages 104-107

  Shayan, Sara ^a   Bokaeian, Mohammad ^a   Shahraki, Shahram ^a  

^a ZAHEDAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAMASE AMPC; CEFOTAXIME; CEFOXITIN; CEFPODOXIME; CEFTAZIDIME; CEFTRIAXONE; PLASMID DNA;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL MUTATION; BACTERIUM ISOLATE; ESCHERICHIA COLI; IRAN; MINIMUM INHIBITORY CONCENTRATION; MULTIPLEX POLYMERASE CHAIN REACTION; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; CEFOXITIN; CEPHALOSPORINS; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; GENE EXPRESSION REGULATION, BACTERIAL; HUMANS; IRAN; MICROBIAL SENSITIVITY TESTS; MUTATION RATE; PLASMIDS;

EID: 84896952661     PISSN: 10766294     EISSN: 19318448     Source Type: Journal    
DOI: 10.1089/mdr.2013.0087     Document Type: Article

References (14)

1. Caroff, N., E. Espaze, D. Gautreau, H. Richet, and A. Reynaud. 2000. Analysis of the effects of-42 and-32 ampC promoter mutations in clinical isolates of Escherichia coli hyperproducing AmpC. J. Antimicrob. Chemother. 45:783-788.
2. Caroff, N., E. Espaze, I. Berard, H. Richet, and A. Reynaud. 1999. Mutations in the ampC promoter of Escherichia coli isolates to oxyiminocephalosporins without extended spectrum b-lactamase production. FEMS Microbiol. Lett. 173: 459-465.
3. [CLSI] Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing, 20th Informational Supplement M100-S20, Clinical and laboratory Standards Institute, Wayne, PA.
4. Corvec, S., N. Caroff, E., Espaze, J. Marraillac, and A. Reynaud. 2002.-11 mutation in the ampC promoter increasing resistance to b-lactams in a clinical Escherichia coli strain. Antimicrobiol. Agents Chemother. 46:3724-3732.
5. Coudron, P.E. 2005. Inhibitor-based methods for detection of plasmid-mediated AmpC b-lactamases in Klebsiella spp., Escherichia coli, and proteus mirabilis. J. Clin. Microbiol. 43:4163-4167.
6. Dallal, M.S., A. Sabaghi, H.M. Aghamirzaeie, A. Raste-garlari, M. Eshraghian, and J. Mehrabad. 2012. Prevalence of AmpC and SHV b-lactamases in clinical isolates of Es-cherichia coli from Tehran Hospitals. J. Microbiol. 16:176-180.
7. Forward, K., B. Willey, D. Low, et al. 2001. Molecular mechanisms of cefoxitin resistance in Escherichia coli from Toronto area hospitals. Diag. Microbiol. Infect. Dis. 41:57-63.
8. Jacoby, G.A. (2009). AmpC beta-lactamases. Clin. Microbiol. Rev. 22:161-182.
9. Jaurin, B., T. Grundstrom, and S. Normark. 1982. Sequence elements determining ampC promoter strength in E. coli. EMBO J. 1:875-881.
10. Manoharan, A., M. Sugumar, A. Kumar, H. Jose, D. Ma-thai, and ICMR-ESBL study group. 2012. Phenotypic & molecular characterization of AmpC b-lactamases among Escherichia coli, Klebsiella spp. & Enterobacter spp. from five Indian Medical Centers. Indian J. Med. Res. 134:359-364.
11. Mansouri, S., D. Kalantar, P. Asadollahi, M. Taherikalani, M. Emaneini. 2012. Characterization of klebsiella pneumonia strains producing extended spectrum beta lactamases and AmpC type beta lactamases isolates from hospitalized patients in Kerman, Iran. Roum. Arch. Microbiol. Immunol. 71:81-86.
12. Mulvey, M.R., E. Bryce, D.A. Boyd, M. Ofner-Agostini, A.M. Land, A.E. Simor, and S. Paton. 2005. Molecular characterisation of cefoxitin-resistant Escherichia coli from Canadian hospitals. Antimicrobiol. Agents Chemother. 49: 358-365.
13. Philippon, A., G. Arlet, G.A. Jacoby. 2002. Plasmid determined AmpC type b-lactamases. Antimicrob. Agents Che-mother. 46:1-11.
14. Pitout, J.D., D.B., Gregson D.L., Church, and K.B. Laupland. 2007. Population-based Laboratory Surveillance for AmpC b-Lactamase-producing Escherichia coli, Calgary. Emerg. Infect. Dis. 13:443-448.